Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A phase I/II study of HD-02, Avicena Group's drug candidate for the treatment of Huntington's disease, has shown that the drug was safe and well-tolerated by patients and to elevate serum and brain levels of creatine.
Subscribe to our email newsletter
Additional findings from the trial showed that serum 8-hydroxy-2′- deoxyguanosine (serum 8OH2’dG) levels, which are markedly elevated in Huntington’s disease patients, were reduced for patients receiving HD-02.
Some researchers believe that this decrease in serum 8OH2’dG may suggest reduced oxidative injury in patients with Huntington’s disease.
“We are very encouraged by the outcome of this important study. Not only did our data show that HD-02 is safe and well-tolerated, but we were also able to collect compelling evidence to indicate that the compound may reduce oxidative injury in patients with Huntington’s disease,” stated Dr Steven Hersch, director of the laboratory of neurodegeneration and neurotherapeutics, Massachusetts General Hospital.
Results from this study, which was supported by the National Center for Complementary and Alternative Medicine were published in the journal Neurology.